Camsirubicin is a small molecule commercialized by Monopar Therapeutics, with a leading Phase II program in Soft Tissue Sarcoma. According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Camsirubicin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Camsirubicin is expected to reach an annual total of $17 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Camsirubicin Overview
camsirubicin is under development for the treatment of advanced soft tissue sarcoma. The drug candidate is a 5-imino-13-deoxydoxorubicin and non-cardiotoxic analog of doxorubicin. It is administered through intravenous route for soft tissue sarcoma, oral route for other additional dermal formulations and applied topically for psoriasis. The drug candidate acts by targeting topoisomerase II alpha.
See Also:
Monopar Therapeutics Overview
Monopar Therapeutics (Monopar) is a clinical-stage biopharmaceutical company. The company’s pipeline products include validive, for chemoradiation-induced SOM; camsirubicin, to treat advanced soft tissue sarcoma; MNPR-101 RIT, to treat advanced solid cancers; MNPR-101ZR, to treat solid cancers; MNPR-202, to treat advanced solid cancers and others. The company’s lead drug product candidate enters clinical development through collaboration with research center in the UK. It also carries out various phases of clinical trials. The company’s brands include Validive. Monopar is headquartered in Wilmette, Illinois, the US.
The operating loss of the company was US$10.5 million in FY2022, compared to an operating loss of US$9.1 million in FY2021. The net loss of the company was US$10.5 million in FY2022, compared to a net loss of US$9.1 million in FY2021.
For a complete picture of Camsirubicin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
